journal
MENU ▼
Read by QxMD icon Read
search

Lancet Oncology

journal
https://www.readbyqxmd.com/read/28318993/nivolumab-activity-in-relapsed-hodgkin-s-lymphoma
#1
Manjulika Das
No abstract text is available yet for this article.
March 16, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28314691/prevention-of-everolimus-related-stomatitis-in-women-with-hormone-receptor-positive-her2-negative-metastatic-breast-cancer-using-dexamethasone-mouthwash-swish-a-single-arm-phase-2-trial
#2
Hope S Rugo, Lasika Seneviratne, J Thaddeus Beck, John A Glaspy, Julio A Peguero, Timothy J Pluard, Navneet Dhillon, Leon Christopher Hwang, Chaitali Nangia, Ingrid A Mayer, Timothy F Meiller, Mark S Chambers, Robert W Sweetman, J Randy Sabo, Jennifer K Litton
BACKGROUND: Stomatitis is a class effect associated with the inhibition of mTOR and is associated with everolimus therapy for breast cancer. Topical steroids might reduce stomatitis incidence and severity, and the need for dose reductions and interruptions of everolimus. Anecdotal use of topical steroid oral prophylaxis has been reported in patients with breast cancer. We aimed to assess dexamethasone-based mouthwash for prevention of stomatitis in patients with breast cancer. METHODS: This US-based, multicentre, single-arm, phase 2 prevention study enrolled women aged 18 years and older with postmenopausal status who had histologically or cytologically confirmed metastatic hormone receptor-positive, HER2-negative breast cancer...
March 14, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28314690/swish-ing-steroids-new-standard-of-care-to-prevent-everolimus-induced-oral-mucositis
#3
Laura Spring, Aditya Bardia
No abstract text is available yet for this article.
March 14, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28314689/dna-methylation-based-classification-and-grading-system-for-meningioma-a-multicentre-retrospective-analysis
#4
Felix Sahm, Daniel Schrimpf, Damian Stichel, David T W Jones, Thomas Hielscher, Sebastian Schefzyk, Konstantin Okonechnikov, Christian Koelsche, David E Reuss, David Capper, Dominik Sturm, Hans-Georg Wirsching, Anna Sophie Berghoff, Peter Baumgarten, Annekathrin Kratz, Kristin Huang, Annika K Wefers, Volker Hovestadt, Martin Sill, Hayley P Ellis, Kathreena M Kurian, Ali Fuat Okuducu, Christine Jungk, Katharina Drueschler, Matthias Schick, Melanie Bewerunge-Hudler, Christian Mawrin, Marcel Seiz-Rosenhagen, Ralf Ketter, Matthias Simon, Manfred Westphal, Katrin Lamszus, Albert Becker, Arend Koch, Jens Schittenhelm, Elisabeth J Rushing, V Peter Collins, Stefanie Brehmer, Lukas Chavez, Michael Platten, Daniel Hänggi, Andreas Unterberg, Werner Paulus, Wolfgang Wick, Stefan M Pfister, Michel Mittelbronn, Matthias Preusser, Christel Herold-Mende, Michael Weller, Andreas von Deimling
BACKGROUND: The WHO classification of brain tumours describes 15 subtypes of meningioma. Nine of these subtypes are allotted to WHO grade I, and three each to grade II and grade III. Grading is based solely on histology, with an absence of molecular markers. Although the existing classification and grading approach is of prognostic value, it harbours shortcomings such as ill-defined parameters for subtypes and grading criteria prone to arbitrary judgment. In this study, we aimed for a comprehensive characterisation of the entire molecular genetic landscape of meningioma to identify biologically and clinically relevant subgroups...
March 14, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28314688/nivolumab-treatment-for-oesophageal-squamous-cell-carcinoma-an-open-label-multicentre-phase-2-trial
#5
Toshihiro Kudo, Yasuo Hamamoto, Ken Kato, Takashi Ura, Takashi Kojima, Takahiro Tsushima, Shuichi Hironaka, Hiroki Hara, Taroh Satoh, Satoru Iwasa, Kei Muro, Hirofumi Yasui, Keiko Minashi, Kensei Yamaguchi, Atsushi Ohtsu, Yuichiro Doki, Yuko Kitagawa
BACKGROUND: Nivolumab is a human monoclonal IgG4 antibody that inhibits programmed cell death protein 1 (PD-1) expressed on activated T cells. We investigated the safety and activity of nivolumab in patients with treatment-refractory oesophageal cancer. METHODS: We did an open-label, single-arm, multicentre phase 2 study. Eligible patients had advanced squamous-cell carcinoma, adenosquamous-cell carcinoma, or adenocarcinoma of the oesophagus refractory or intolerant to fluoropyrimidine-based, platinum-based, and taxane-based chemotherapy...
March 14, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28314687/immune-checkpoint-inhibition-for-digestive-cancers
#6
Sylvain Manfredi, Antoine Drouillard
No abstract text is available yet for this article.
March 14, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28314686/epigenetics-a-new-tool-for-meningioma-management
#7
Marc Sanson, Michel Kalamarides
No abstract text is available yet for this article.
March 14, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28291584/clinical-safety-and-activity-of-pembrolizumab-in-patients-with-malignant-pleural-mesothelioma-keynote-028-preliminary-results-from-a-non-randomised-open-label-phase-1b-trial
#8
Evan W Alley, Juanita Lopez, Armando Santoro, Anne Morosky, Sanatan Saraf, Bilal Piperdi, Emilie van Brummelen
BACKGROUND: Malignant pleural mesothelioma is a highly aggressive cancer with poor prognosis and few treatment options following progression on platinum-containing chemotherapy. We assessed the safety and efficacy of pembrolizumab (an anti-programmed cell death receptor 1 [PD-1] antibody) in advanced solid tumours expressing programmed cell death ligand 1 (PD-L1) and report here on the interim analysis of the malignant pleural mesothelioma cohort. METHODS: Previously treated patients with PD-L1-positive malignant pleural mesothelioma were enrolled from 13 centres in six countries...
March 10, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28285843/pravastatin-has-no-advantage-in-small-cell-lung-cancer
#9
Vicki Brower
No abstract text is available yet for this article.
March 9, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28285842/blinatumomab-significantly-improves-overall-survival
#10
Talha Khan Burki
No abstract text is available yet for this article.
March 9, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28285841/treating-chemotherapy-induced-peripheral-neuropathy
#11
Manjulika Das
No abstract text is available yet for this article.
March 9, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28284558/a-step-forward-for-patients-with-nras-mutant-melanoma
#12
Michael A Postow, Paul B Chapman
No abstract text is available yet for this article.
March 8, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28284557/binimetinib-versus-dacarbazine-in-patients-with-advanced-nras-mutant-melanoma-nemo-a-multicentre-open-label-randomised-phase-3-trial
#13
Reinhard Dummer, Dirk Schadendorf, Paolo A Ascierto, Ana Arance, Caroline Dutriaux, Anna Maria Di Giacomo, Piotr Rutkowski, Michele Del Vecchio, Ralf Gutzmer, Mario Mandala, Luc Thomas, Lev Demidov, Claus Garbe, David Hogg, Gabriella Liszkay, Paola Queirolo, Ernesto Wasserman, James Ford, Marine Weill, L Andres Sirulnik, Valentine Jehl, Viviana Bozón, Georgina V Long, Keith Flaherty
BACKGROUND: There are no established therapies specific for NRAS-mutant melanoma despite the emergence of immunotherapy. We aimed to assess the efficacy and safety of the MEK inhibitor binimetinib versus that of dacarbazine in patients with advanced NRAS-mutant melanoma. METHODS: NEMO is an ongoing, randomised, open-label phase 3 study done at 118 hospitals in 26 countries. Patients with advanced, unresectable, American Joint Committee on Cancer stage IIIC or stage IV NRAS-mutant melanoma who were previously untreated or had progressed on or after previous immunotherapy were randomised (2:1) to receive either binimetinib 45 mg orally twice daily or dacarbazine 1000 mg/m(2) intravenously every 3 weeks...
March 8, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28283283/drug-development-in-prostate-cancer-time-to-embrace-recist
#14
Guru Sonpavde, Andrew J Armstrong
No abstract text is available yet for this article.
March 7, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28283282/custirsen-in-combination-with-docetaxel-and-prednisone-for-patients-with-metastatic-castration-resistant-prostate-cancer-synergy-trial-a-phase-3-multicentre-open-label-randomised-trial
#15
Kim N Chi, Celestia S Higano, Brent Blumenstein, Jean-Marc Ferrero, James Reeves, Susan Feyerabend, Gwenaelle Gravis, Axel S Merseburger, Arnulf Stenzl, Andries M Bergman, Som D Mukherjee, Pawel Zalewski, Fred Saad, Cindy Jacobs, Martin Gleave, Johann S de Bono
BACKGROUND: Clusterin is a chaperone protein associated with treatment resistance and upregulated by apoptotic stressors such as chemotherapy. Custirsen is a second-generation antisense oligonucleotide that inhibits clusterin production. The aim of the SYNERGY trial was to investigate the effect of custirsen in combination with docetaxel and prednisone on overall survival in patients with metastatic castration-resistant prostate cancer. METHODS: SYNERGY was a phase 3, multicentre, open-label, randomised trial set at 134 study centres in 12 countries...
March 7, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28274756/common-genetic-variation-and-risk-of-gallbladder-cancer-in-india-a-case-control-genome-wide-association-study
#16
Sharayu Mhatre, Zhaoming Wang, Rajini Nagrani, Rajendra Badwe, Shubhada Chiplunkar, Balraj Mittal, Saurabh Yadav, Haoyu Zhang, Charles C Chung, Prachi Patil, Stephen Chanock, Rajesh Dikshit, Nilanjan Chatterjee, Preetha Rajaraman
BACKGROUND: Gallbladder cancer is highly lethal, with notable differences in incidence by geography and ethnic background. The aim of this study was to identify common genetic susceptibility alleles for gallbladder cancer. METHODS: In this case-control genome-wide association study (GWAS), we did a genome-wide scan of gallbladder cancer cases and hospital visitor controls, both of Indian descent, followed by imputation across the genome. Cases were patients aged 20-80 years with microscopically confirmed primary gallbladder cancer diagnosed or treated at Tata Memorial Hospital, Mumbai, India, and enrolled in the study between Sept 12, 2010, and June 8, 2015...
March 3, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28268065/a-second-chance-for-success-with-braf-and-mek-inhibitors-in-melanoma
#17
Kelly G Paulson, John A Thompson
No abstract text is available yet for this article.
March 3, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28268064/combination-of-dabrafenib-plus-trametinib-for-braf-and-mek-inhibitor-pretreated-patients-with-advanced-braf-v600-mutant-melanoma-an-open-label-single-arm-dual-centre-phase-2-clinical-trial
#18
Max Schreuer, Yanina Jansen, Simon Planken, Ines Chevolet, Teofila Seremet, Vibeke Kruse, Bart Neyns
BACKGROUND: Patients with BRAF(V600)-mutant melanoma benefit from treatment with the combination of BRAF and MEK inhibitors, but resistance and disease progression develops in most patients. Preclinical studies and case studies have indicated that acquired resistance to BRAF inhibition can be reversible. We aimed to assess the anti-tumour activity of rechallenge with BRAF plus MEK inhibition in a prospective clinical trial. METHODS: In this open-label, single arm, dual-centre, phase 2 academic study in Belgium, patients aged 18 years or older with BRAF(V600)-mutant melanoma who had previously progressed on BRAF inhibitors (with or without MEK inhibitors) and were off-treatment for at least 12 weeks, were treated with dabrafenib 150 mg orally twice per day plus trametinib 2 mg orally once per day...
March 3, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28262462/correction-to-lancet-oncol-2017-18-347-56
#19
(no author information available yet)
No abstract text is available yet for this article.
March 2, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28262461/clofarabine-based-consolidation-therapy-in-aml
#20
Vicki Brower
No abstract text is available yet for this article.
March 2, 2017: Lancet Oncology
journal
journal
20189
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"